PCRX Pacira BioSciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

PCRX [NASD]

Pacira BioSciences, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.25	Insider Own	1.30%	Shs Outstand	42.22M	Perf Week	-6.67%
Market Cap	2.40B	Forward P/E	13.94	EPS next Y	3.89	Insider Trans	-51.73%	Shs Float	39.50M	Perf Month	-10.46%
Income	-10.10M	PEG	-	EPS next Q	0.61	Inst Own	-	Short Float	14.35%	Perf Quarter	0.56%
Sales	408.30M	P/S	5.88	EPS this Y	22.80%	Inst Trans	0.29%	Short Ratio	10.89	Perf Half Y	39.33%
Book/sh	9.19	P/B	5.89	EPS next Y	89.52%	ROA	-1.20%	Target Price	66.08	Perf Year	37.21%
Cash/sh	7.37	P/C	7.35	EPS next 5Y	31.00%	ROE	-2.80%	52W Range	27.46 - 64.44	Perf YTD	19.58%
Dividend	-	P/FCF	183.27	EPS past 5Y	7.30%	ROI	1.50%	52W High	-15.72%	Beta	1.11
Dividend %	-	Quick Ratio	5.50	Sales past 5Y	16.30%	Gross Margin	74.00%	52W Low	97.78%	ATR	2.40
Employees	606	Current Ratio	6.50	Sales Q/Q	-26.40%	Oper. Margin	3.40%	RSI (14)	35.23	Volatility	5.25% 4.09%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-367.10%	Profit Margin	-2.50%	Rel Volume	0.49	Prev Close	54.17
Shortable	Yes	LT Debt/Eq	0.81	Earnings	Aug 06 BMO	Payout	-	Avg Volume	520.62K	Price	54.31
Recom	2.10	SMA20	-6.07%	SMA50	-8.78%	SMA200	13.00%	Volume	253,858	Change	0.26%

Sep-21-20

Upgrade

Northland Capital

Market Perform → Outperform

$58 → $67

Jul-06-20

Reiterated

Needham

Buy

$52 → $64

May-27-20

Initiated

Guggenheim

Neutral

Apr-07-20

Initiated

Northland Capital

Outperform

$50

Mar-20-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$44

Feb-24-20

Reiterated

H.C. Wainwright

Buy

$60 → $63

Jan-24-20

Initiated

SunTrust

Buy

Jan-23-20

Initiated

SunTrust

Buy

Nov-06-19

Initiated

BTIG Research

Buy

$56

Jun-11-19

Initiated

Barclays

Overweight

$52

May-06-19

Upgrade

Mizuho

Underperform → Neutral

$29 → $38

May-02-19

Upgrade

Stifel

Sell → Hold

$45

Feb-01-19

Downgrade

Mizuho

Neutral → Underperform

Aug-06-18

Downgrade

BofA/Merrill

Buy → Neutral

Apr-09-18

Reiterated

H.C. Wainwright

Buy

$45 → $48

Mar-21-18

Reiterated

Mizuho

Neutral

$44 → $31

Feb-16-18

Downgrade

Needham

Buy → Hold

Jan-19-18

Initiated

Seaport Global Securities

Buy

$50

Jan-04-18

Reiterated

Canaccord Genuity

Buy

$42 → $46

Jan-03-18

Initiated

Leerink Partners

Mkt Perform

$46

Oct-22-20 12:33PM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Oct-21-20 07:30AM	Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain GlobeNewswire
06:25AM	Pacira BioSciences (PCRX) Enters Oversold Territory Zacks
Oct-20-20 07:30AM	Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020 GlobeNewswire
Oct-19-20 11:30AM	Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year? Zacks
Oct-07-20 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020 GlobeNewswire
Sep-21-20 11:56AM	Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU Zacks
Sep-18-20 08:07AM	Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain GlobeNewswire
Sep-16-20 02:55PM	Here is What Hedge Funds Think About Pacira Biosciences Inc (PCRX) Insider Monkey
Sep-15-20 07:30AM	IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs GlobeNewswire
Sep-11-20 07:30AM	Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-09-20 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020 GlobeNewswire
Sep-05-20 11:31AM	Pacira (PCRX) Up 4.1% Since Last Earnings Report: Can It Continue? Zacks
Aug-06-20 08:00AM	Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update GlobeNewswire
Aug-05-20 04:05PM	Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
07:30AM	Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia GlobeNewswire
Aug-04-20 07:30AM	Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients GlobeNewswire
Jul-30-20 07:30AM	Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020 GlobeNewswire
Jul-28-20 05:03PM	Pacira BioSciences Announces Settlement of Government Investigation GlobeNewswire
Jul-12-20 12:43PM	Did Hedge Funds Make The Right Call On Pacira Biosciences Inc (PCRX)? Insider Monkey
Jul-07-20 07:51PM	Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025 GlobeNewswire
Jul-06-20 04:02PM	Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes GlobeNewswire
04:01PM	Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020 GlobeNewswire
Jul-02-20 07:30AM	Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes GlobeNewswire
Jun-29-20 09:00AM	U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller Reuters +17.99%
Jun-16-20 07:30AM	Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-10-20 04:36PM	Hedge Funds Souring On Pacira Biosciences Inc (PCRX) Insider Monkey
May-27-20 07:30AM	Pacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference GlobeNewswire
May-13-20 07:30AM	Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference GlobeNewswire
May-07-20 08:00AM	Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update GlobeNewswire
May-04-20 07:30AM	Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer GlobeNewswire +5.42%
Apr-30-20 07:30AM	Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 GlobeNewswire
Apr-23-20 08:59AM	Why Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Matters To You Simply Wall St.
Apr-07-20 05:00PM	Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds? Insider Monkey
Apr-06-20 08:00AM	How This Top Fund Manager Seeks Stocks That Benefit From The Coronavirus Stock Market Investor's Business Daily
Mar-21-20 11:30AM	Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-17-20 09:53AM	Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock Zacks
Mar-13-20 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why Zacks +5.98%
11:40AM	PCRX or ZTS: Which Is the Better Value Stock Right Now? Zacks
Mar-10-20 10:24AM	Why Pacira (PCRX) Could Be an Impressive Growth Stock Zacks
Mar-09-20 07:30AM	Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference GlobeNewswire -8.35%
Mar-05-20 07:44AM	The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group Zacks
Mar-04-20 09:22AM	Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall Zacks
Feb-27-20 12:32AM	Edited Transcript of PCRX earnings conference call or presentation 20-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -5.14%
Feb-26-20 12:45PM	3 Reasons Why Pacira (PCRX) Is a Great Growth Stock Zacks
11:40AM	PCRX vs. ZTS: Which Stock Is the Better Value Option? Zacks
Feb-23-20 09:46AM	Pacira BioSciences, Inc. Released Earnings Last Week And Analysts Lifted Their Price Target To US$58.60 Simply Wall St.
Feb-21-20 10:22AM	Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line Zacks
09:45AM	Should You Be Worried About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) 0.6% Return On Equity? Simply Wall St.
Feb-20-20 08:00AM	Pacira Reports Record Fourth Quarter and Full-Year Revenues GlobeNewswire
Feb-19-20 09:21AM	3 Top-Ranked Stocks Poised for an Earnings Beat Zacks
Feb-13-20 07:30AM	Pacira to Report 2019 Financial Results on Thursday February 20, 2020 GlobeNewswire
Feb-12-20 09:45AM	FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA Zacks
Feb-11-20 06:39AM	Will Pacira BioSciences Continue to Surge Higher? Zacks
Feb-07-20 06:52AM	The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge Zacks
Feb-06-20 08:36AM	The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences Zacks
08:10AM	5 Big Winners From Trump's State of the Union Address Zacks
Feb-05-20 08:37AM	4 Top Growth Stocks to Buy as Coronavirus Fears Subside Zacks
Feb-03-20 08:53AM	Pacira BioSciences Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-22-20 08:53AM	Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8% Zacks
Jan-21-20 09:06AM	New Strong Buy Stocks for January 21st Zacks
07:30AM	Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services GlobeNewswire
Jan-13-20 11:40AM	ASRT or PCRX: Which Is the Better Value Stock Right Now? Zacks
Jan-09-20 07:30AM	Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million GlobeNewswire
Jan-08-20 11:16AM	Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study Zacks
07:30AM	Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-07-20 02:08PM	Does Pacira BioSciences, Inc. (NASDAQ:PCRX) Have A Volatile Share Price? Simply Wall St.
10:21AM	Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study Zacks
07:30AM	EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients GlobeNewswire
Dec-27-19 11:40AM	ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Dec-26-19 11:52AM	2019 Review: Top Hedge Fund Stocks vs. Pacira BioSciences, Inc. (PCRX) Insider Monkey
Dec-18-19 09:23AM	Pacira's Late-Stage Study on Exparel Label Expansion Positive Zacks
Dec-17-19 07:30AM	Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients GlobeNewswire
Dec-16-19 03:44PM	Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern Zacks
Dec-10-19 11:40AM	ASRT vs. PCRX: Which Stock Should Value Investors Buy Now? Zacks
Dec-07-19 11:31AM	Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 08:03PM	Is Pacira BioSciences, Inc. (PCRX) A Good Stock To Buy? Insider Monkey
Nov-26-19 07:30AM	Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-13-19 11:00AM	Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Justified? Simply Wall St.
07:30AM	Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
05:51AM	Edited Transcript of PCRX earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-19 11:31AM	Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y Zacks
Nov-07-19 09:25AM	Pacira (PCRX) Q3 Earnings Surpass Estimates Zacks
08:00AM	Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire
Oct-31-19 10:33AM	Pacira (PCRX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-30-19 09:15AM	Small Step Back Ahead of Fed, Apple Zacks
Oct-28-19 09:26AM	Is Pacira BioSciences, Inc. (PCRX) A Good Stock To Buy? Insider Monkey
Oct-25-19 07:30AM	Pacira to Report Third Quarter 2019 Financial Results on Thursday November 7, 2019 GlobeNewswire
Oct-11-19 11:01AM	Introducing Pacira BioSciences (NASDAQ:PCRX), The Stock That Slid 64% In The Last Five Years Simply Wall St.
Oct-02-19 09:15AM	Rough Start to Fourth Quarter Zacks
Sep-24-19 06:09PM	Pacira BioSciences Set to Join S&P SmallCap 600 PR Newswire
Sep-19-19 07:30AM	Pacira BioSciences Appoints Chris Christie to Board of Directors GlobeNewswire
Sep-17-19 07:30AM	Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients GlobeNewswire
Sep-07-19 09:30AM	Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound? Zacks
Sep-05-19 07:44AM	Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment? Simply Wall St.
Aug-30-19 06:14PM	5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Aug-19-19 09:30AM	ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Aug-16-19 07:15PM	Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $503,038 of Shares GuruFocus.com
Aug-09-19 11:02AM	Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-08-19 06:12PM	Pacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript Motley Fool

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STACK DAVID M	CEO and Chairman	Oct 16	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 16	Sale	55.56	30,000	1,666,800	173,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 15	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 15	Sale	55.00	30,000	1,650,000	173,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 14	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 14	Sale	55.53	30,000	1,665,900	173,377	Oct 16 04:26 PM
PACE GARY W	Director	Sep 25	Option Exercise	16.67	70,000	1,166,900	129,949	Sep 29 05:16 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 17	Option Exercise	39.19	27,871	1,092,268	52,758	Sep 17 07:13 PM
REINHARDT MAX	President	Sep 17	Option Exercise	42.54	25,000	1,063,500	39,000	Sep 21 06:23 PM
REINHARDT MAX	President	Sep 17	Sale	59.81	25,420	1,520,318	14,000	Sep 21 06:23 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 17	Sale	59.82	27,871	1,667,290	24,887	Sep 17 07:13 PM
Riker Lauren Bullaro	Vice President, Finance	Sep 16	Option Exercise	10.81	3,000	32,430	16,181	Sep 17 07:10 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 16	Option Exercise	39.19	27,853	1,091,560	52,740	Sep 17 07:13 PM
Riker Lauren Bullaro	Vice President, Finance	Sep 16	Sale	60.34	3,000	181,020	13,181	Sep 17 07:10 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 16	Sale	60.14	27,853	1,675,150	24,887	Sep 17 07:13 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 15	Option Exercise	39.19	27,853	1,091,560	52,740	Sep 17 07:13 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 15	Sale	59.39	27,853	1,654,058	24,887	Sep 17 07:13 PM
Wicki Andreas	Director	Sep 09	Sale	62.02	2,216	137,436	692,970	Sep 11 08:03 PM
STACK DAVID M	CEO and Chairman	Aug 17	Sale	61.91	15,000	928,619	173,377	Aug 19 05:44 PM
Wicki Andreas	Director	Aug 13	Sale	61.47	34,904	2,145,549	695,186	Aug 13 08:58 PM
Wicki Andreas	Director	Aug 12	Sale	60.82	113,500	6,903,070	730,090	Aug 13 08:58 PM
Riker Lauren Bullaro	Vice President, Finance	Aug 11	Option Exercise	10.34	8,180	84,581	20,813	Aug 13 04:35 PM
Wicki Andreas	Director	Aug 11	Sale	61.32	106,772	6,546,747	843,590	Aug 13 08:58 PM
Riker Lauren Bullaro	Vice President, Finance	Aug 11	Sale	60.50	8,180	494,890	13,181	Aug 13 04:35 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Aug 03	Option Exercise	44.10	2,500	110,250	22,750	Aug 05 05:16 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Aug 03	Sale	52.68	2,500	131,700	20,796	Aug 05 05:16 PM
STACK DAVID M	CEO and Chairman	Jul 15	Sale	56.88	12,000	682,560	188,377	Jul 17 05:44 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 29	Option Exercise	10.34	6,000	62,040	18,633	Jul 01 09:20 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Jun 29	Option Exercise	42.07	56,250	2,366,588	80,351	Jul 01 09:17 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 29	Sale	49.47	6,000	296,800	12,633	Jul 01 09:20 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Jun 29	Sale	50.27	60,101	3,021,314	20,250	Jul 01 09:17 PM
STACK DAVID M	CEO and Chairman	Jun 08	Sale	48.12	17,111	823,402	166,909	Jun 08 09:09 PM
Brege Laura	Director	Jun 05	Sale	48.70	2,100	102,270	6,661	Jun 08 09:04 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 05	Sale	48.37	1,752	84,744	7,833	Jun 08 09:08 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 05	Sale	48.61	5,904	286,993	10,887	Jun 08 09:10 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 04	Sale	46.33	2,402	111,287	16,791	Jun 08 09:10 PM
STACK DAVID M	CEO and Chairman	Jun 04	Sale	46.33	14,314	663,182	184,020	Jun 08 09:09 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 04	Sale	46.33	879	40,725	9,585	Jun 08 09:08 PM
McLoughlin Dennis	Chief Commercial Officer	Jun 04	Sale	46.33	1,447	67,041	14,898	Jun 08 09:07 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 04	Sale	46.33	1,489	68,987	14,847	Jun 08 09:07 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Jun 04	Sale	46.33	863	39,984	10,101	Jun 08 09:06 PM
HASTINGS PAUL J	Director	Jun 04	Sale	47.46	2,025	96,107	4,856	Jun 08 09:05 PM
Riker Lauren Bullaro	Vice President, Finance	May 21	Option Exercise	10.34	2,000	20,680	12,464	May 21 07:19 PM
Riker Lauren Bullaro	Vice President, Finance	May 21	Sale	45.26	2,000	90,520	10,464	May 21 07:19 PM
Riker Lauren Bullaro	Vice President, Finance	May 19	Option Exercise	10.34	2,000	20,680	12,464	May 21 07:19 PM
Riker Lauren Bullaro	Vice President, Finance	May 19	Sale	42.81	2,000	85,620	10,464	May 21 07:19 PM
PACE GARY W	Director	Mar 12	Option Exercise	4.46	21,736	96,845	58,689	Mar 16 05:54 PM
LONGENECKER JOHN P PHD	Director	Mar 12	Option Exercise	1.61	3,736	6,015	16,497	Mar 16 05:53 PM
WINSTON ROY	Chief Clinical Officer	Mar 11	Buy	36.50	2,500	91,250	25,237	Mar 12 07:18 PM
STACK DAVID M	CEO and Chairman	Feb 21	Option Exercise	3.38	35,856	121,189	198,334	Feb 25 04:55 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 10	Option Exercise	10.81	3,000	32,430	13,464	Feb 12 04:41 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 10	Sale	48.81	3,000	146,430	10,464	Feb 12 04:41 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 07	Option Exercise	10.81	170	1,838	10,634	Feb 10 06:19 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 07	Sale	46.81	170	7,958	10,464	Feb 10 06:19 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 06	Option Exercise	10.81	830	8,972	11,294	Feb 10 06:19 PM
Riker Lauren Bullaro	Vice President, Finance	Feb 06	Sale	46.81	830	38,852	10,464	Feb 10 06:19 PM
STACK DAVID M	CEO and Chairman	Jan 15	Option Exercise	10.81	25,000	270,250	26,208	Jan 17 06:13 PM
STACK DAVID M	CEO and Chairman	Jan 15	Sale	42.68	25,000	1,066,968	1,208	Jan 17 06:13 PM
STACK DAVID M	CEO and Chairman	Dec 26	Option Exercise	3.55	20,000	71,000	162,299	Dec 30 04:05 PM
Riker Lauren Bullaro	Vice President, Finance	Dec 23	Option Exercise	10.81	1,000	10,810	11,464	Dec 26 04:08 PM
Riker Lauren Bullaro	Vice President, Finance	Dec 23	Sale	45.92	1,000	45,920	10,464	Dec 26 04:08 PM
McLoughlin Dennis	Chief Commercial Officer	Dec 16	Sale	45.79	3,671	168,108	16,116	Dec 18 06:54 PM
LONGENECKER JOHN P PHD	Director	Dec 02	Option Exercise	1.61	4,000	6,440	14,061	Dec 04 04:46 PM
LONGENECKER JOHN P PHD	Director	Dec 02	Sale	46.13	1,300	59,972	12,761	Dec 04 04:46 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 20	Option Exercise	10.81	1,000	10,810	11,640	Nov 22 07:28 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 20	Sale	44.14	1,176	51,909	10,464	Nov 22 07:28 PM
STACK DAVID M	CEO and Chairman	Nov 15	Option Exercise	10.81	25,000	270,250	26,208	Nov 19 04:16 PM
STACK DAVID M	CEO and Chairman	Nov 15	Sale	42.81	25,000	1,070,250	1,208	Nov 19 04:16 PM
STACK DAVID M	CEO and Chairman	Nov 15	Sale	42.81	45,000	1,926,450	142,299	Nov 19 04:16 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 11	Option Exercise	10.36	5,000	51,785	15,640	Nov 12 05:12 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 11	Sale	43.59	5,000	217,950	10,640	Nov 12 05:12 PM
Scranton Richard	Chief Scientific Officer	Nov 08	Option Exercise	14.37	19,448	279,393	35,509	Nov 12 05:10 PM
Scranton Richard	Chief Scientific Officer	Nov 08	Sale	45.00	19,448	875,160	16,061	Nov 12 05:10 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience